Tekmira raises $30 million in follow-on

Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR) raised $30 million on Thursday through the sale of 3.8 million shares at $8 in a follow-on underwritten by Stifel and Maxim Group. Tekmira proposed the offering late Wednesday, when its share price on NASDAQ was $8.82. Tekmira's lead internal candidate is TKM-PLK1, which is in Phase I/II testing to treat advanced gastrointestinal neuroendocrine tumors and adrenocortical carcinoma, with data expected in mid-2014. TKM-PLK1 comprises short interfering RNA (siRNA) targeting polo-like kinase 1 (PLK1; STPK13) formulated with the company's lipid nanoparticle (LNP) technology. ...